Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia. Elisabetta Vaudano DVM PhD, Coordinator Scientific Pillar, Principal Scientific Manager, Innovative Medicines Initiative

1. - Innovative Medicines Initiative -
Elisabetta Vaudano

2.  Open collaboration in public-private consortia
(data sharing, dissemination of results)
 “Non-competitive” collaborative
research for EFPIA pharma
companies
 Competitive calls to select partners of
EFPIA companies
Key Concepts of IMI

3. REGULATORS ON
BOARD OF
12
PROJECTS
50%of projects have
REGULATORY AUTHORITIES
representatives in Scientific
Advisory Boards
61%of projects
reported some form of
PATIENT
INVOLVEMENT

4. Key collaborative activity areas:
Diabetes, CNS disorders, Tuberculosis, Patient Reported Outcomes,
Cancer, Preclinical Safety and Education & Training.
IMI signed horizontal agreements with:
Critical Path, Juvenile Diabetes Research Foundation as well as
with Clinical Data Interchange Standards Consortium.
Collaboration

5. € 1 945 135 308
€ 759,185,796
Infectious diseases
€ 214,136,227
Drug discovery
€ 182,980,698
Brain disorders
€ 116,880,300
Metabolic disorders
€ 116,287,312
Drug safety
€ 78,225,417
Stem cells
€ 72,710786
Cancer
IMI funding
Corporate contribution
€ 70,310,746
Data management
€ 69,739,527
Inflammatory disorders
€ 55,930,958
Biologicals
€ 49,310,000
Geriatrics
€ 37,966,496
Lung diseases
€ 37,378,289
Education and
training
€ 30,601,855
Sustainable
chemistry
€ 20,426,255
Drug delivery
€ 18,118,249
Drug kinetics
€ 14,910,397
Relative effectiveness
NATURE MEDICINE | NEWS
Partners
AiCuris Johnson&Johnson
Animal Health Medimmune
Division of Sanofi Merck
Astellas Merck Sharp
AstraZeneca & Dohme Corp
Basilea Merial
Boehringer Ingelheim Novartis
Cubist Pfizer
GSK Rempex
Janssen Sanofi
AstraZeneca Novartis
Bayer Pfizer
Janssen Sanofi
Lundbeck UCB
Merck
Abbott Janssen
AbbVie Lundbeck
AC IMMUNE Merck
Amgen Novartis
Astellas NOVO NORDISK
AstraZeneca Orion Corporation
BIOGEN IDEC Pfizer
Boehringer Ingelheim Roche
Eisai Sanofi
Eli Lilly SERVIER
ESTEVE UCB
Grunenthal Vifor
GSK
First phase of Europe’s IMI effort: budget breakdown

6. IMI invests €167 million in 4 projects aiming at:
 Developing models to predict the efficacy of drug candidates in patients
 Connecting data on 40 millions of individuals to decipher links between
genetic background, biological abnormalities, brain imaging changes,
mental symptoms and disease progression
 Identifying subgroups of the disease allowing to tailor therapies according
to the different causal factors involved
 Implementing innovative trial designs
How IMI addresses Alzheimer’s disease

7. January 2014

8. The Vision for IMI2 – The right prevention and
treatment for the right patient at the right time
Biologically
heterogeneous
patient population
Graphic adapted from C. Carini, C. Fratazzi, Eur. Pharm. Rev. 2008, 2, 39-45
effective
not
effective
Adverse
events
Trial and Error
effective
not
effective
adverse
events
Dx
Test
A
B
Ce.g.
biomarker
Information based
treatment decisions
vs
The Next Phase: IMI2

9. IMI2 Key Facts and Strategic Research
Agenda
Bigger budget: 3,45 Billion
Euro, equally shared by EU
and industry
Partnership Not limited to
EFPIA members
Dementia and
Neurodegeneration have
been identified as key
research priorities

10. Thank you
www.imi.europa.eu
@IMI_JU